Mezzion Pharma Secures $20 Million in Funding for Phase 3 Clinical Development of Udenafil. The financing was led by Midas-Meritz and KDBC to support trials for Fontan patients.
Amount Raised
$20 Million
Round Type
Funding Round
Fort LeeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Mezzion Pharma Co., Ltd. announced a major milestone by securing approximately $20 million in strategic funding. The financing was led by Midas-Meritz and KDBC, showing strong confidence from top-tier investors in Mezzion's late-stage pipeline. This funding will support the ongoing global Phase 3 trial of udenafil for patients with Fontan circulation
Quick answer
Mezzion Pharma raised $20 Million in a Funding Round round, dated June 11, 2025. Investors: Kdbc Korea Investment & Securities New Technology Investment Association and Midas Meritz New Technology Finance Association. Mezzion Pharma is based in Fort Lee, New Jersey, United States.
- How much did Mezzion Pharma raise?
- Mezzion Pharma raised $20 Million in a Funding Round round on June 11, 2025.
- Who invested in Mezzion Pharma?
- Kdbc Korea Investment & Securities New Technology Investment Association and Midas Meritz New Technology Finance Association are named as investors in this round.
- What does Mezzion Pharma do?
- Mezzion Pharmaceuticals, Inc., a U.S.-based subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company focused on developing therapies for rare and underserved diseases.
- Where is Mezzion Pharma based and how big is it?
- Mezzion Pharma is based in Fort Lee, New Jersey, United States.
- Who are the decision-makers at Mezzion Pharma?
- Fundz holds 1 contact at Mezzion Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Mezzion Pharma that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $4.2M on June 23, 2025.
- Ensho Therapeutics raised $23M on June 12, 2025.
- DiaMedica Therapeutics raised $30M on July 23, 2025.
- DiaMedica Therapeutics raised $30M (Post-IPO Equity) on July 21, 2025.
- GenSight Biologics raised $580K (Seed) on July 17, 2025.
- BioSapien raised $8M (Pre-Series A) on July 7, 2025.
Who to call at Mezzion Pharma, and when
A new round usually means Mezzion Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Mezzion Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mezzion Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mezzion Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mezzion Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Mezzion Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.